[ad_1]
Declaration of Conditional Special Interim Dividend
HONG KONG SAR – Media OutReach – 15 January 2021 – Jacobson Pharma Corporation Limited (“Jacobson Pharma” or the “Company”; Stock Code: 2633), a number one firm engaged within the analysis, improvement, manufacturing, advertising and sale of generic medicine and proprietary medicines, at present introduced the declaration of a conditional particular interim dividend by means of a distribution in specie of an combination of 241,777,625 JBM Shares, representing roughly 27.1% of the full variety of JBM Shares in concern instantly upon completion of the proposed spin-off, to the qualifying shareholders.
As of at present, the full variety of issued shares of the Company (“Shares”) is 1,934,221,000. Assuming there is no such thing as a change within the complete variety of shares from at present as much as 29 January 2021 (the “Record Date”), the qualifying shareholders will obtain one JBM Share for each eight Shares held on the Record Date.
The distribution is conditional on the general public supply turning into unconditional in all respects. If such situation isn’t happy, the proposed spin-off is not going to happen and the distribution is not going to be made.
For extra particulars, please discuss with the hyperlink of announcement: https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0115/2021011501333.pdf
About Jacobson Pharma Corporation Limited (雅各臣科研製藥有限公司；Stock Code: 2633)
Jacobson Pharma is a number one generic drug firm in Hong Kong. The Group additionally carries a portfolio of proprietary manufacturers, notably Po Chai Pills (「保濟丸」), Ho Chai Kung TjiThung San (「何濟公止痛退熱散」), Contractubex Scar Gel (「秀碧除疤膏」), Flying Eagle Woodlok Oil (「飛鷹活絡油」), Tong Tai Chung Woodlok Oil (「唐太宗活絡油」), Doan’s Ointment (「兜安氏藥膏」), Saplingtan (「十靈丹」), Shiling Oil (「十靈油」) and Col-gan Tablet (「傷風克」), which have been broadly recognised by the market. In the strategic enlargement of its branded healthcare enterprise platform, the Group has launched well being and wellness manufacturers and merchandise comparable to Dr. Freeman®Flu/RSV Combo (「Dr. Freeman醫臣®流感／呼吸道合胞病毒家用式診斷套件」), SmartfishWell being Nutrition Products (「Smartfish健康營養產品」), Dr. Freeman® Infection Control Product Series (「Dr. Freeman醫臣®感染控制產品系列」) and Dr Freeman COVID-19 Rapid Test Kit (「Dr. Freeman醫臣®COVID-19快速測試套件」), amongst different respected manufacturers represented in abroad markets comparable to Excilor and Weisen-U.
The Group goals on the continued strategic enrichment of each of its generic drug and branded healthcare portfolios by way of the addition of excessive value-added merchandise. With its company headquarters primarily based in Hong Kong, the Group has additionally established its working subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional business platform to faucet the market potential within the Asia Pacific and Greater China area. Jacobson Pharma has been a constituent inventory of MSCI Hong Kong Micro Cap Index since 1 June 2017. For extra particulars about Jacobson Pharma, please go to the Group’s web site: http://www.jacobsonpharma.com
[ad_2]
Source link
